All In Biotech

Drug Trial Radar · NCT02045797

Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

A Phase II, Randomized, Two-Part, Multicenter, Dose-Ranging Study in Adult Subjects Evaluating the Safety, Tolerability, and Efficacy of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 20, 2026Latest source record: Nov 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Mar 24, 2014

Primary completion

Jun 29, 2015

Study completion Jun 29, 2015

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jan 27, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

GSK2140944 belongs to a novel structural class of antibiotics - Bacterial Type II Topoisomerase Inhibitors (BTI). This is a Phase II, randomized, two-part, multicenter study designed to select the optimal dose by further characterizing the safety, tolerability and PK of GSK 2140944 and by evaluating efficacy in subjects requiring in-patient medical care to treat their suspected or confirmed Gram-positive acute bacterial skin and skin structure infections (ABSSSI). The selected dose will be used in future studies.

Conditions

  • Infections, Bacterial

Interventions

  • GSK2140944 LyophileDrug

    GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.

  • GSK2140944 CapsulesDrug

    GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Composite of the Cure Rate as Measured by Clinical Response and Outcome at the Early Efficacy Visit Combined With Withdrawal RateTime frame: Up to Day 3

Locations

30 sites in 1 country. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Anaheim, California

  • GSK Investigational Site

    Chula Vista, California

  • GSK Investigational Site

    La Mesa, California

  • GSK Investigational Site

    Oceanside, California

  • GSK Investigational Site

    Sylmar, California

  • GSK Investigational Site

    Torrance, California

  • GSK Investigational Site

    Miramar, Florida

  • GSK Investigational Site

    West Palm Beach, Florida

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Augusta, Georgia

  • GSK Investigational Site

    Council Bluffs, Iowa

  • GSK Investigational Site

    Hazard, Kentucky

  • GSK Investigational Site

    Zachary, Louisiana

  • GSK Investigational Site

    Minneapolis, Minnesota

  • GSK Investigational Site

    Carriere, Mississippi

  • GSK Investigational Site

    Jackson, Mississippi

  • GSK Investigational Site

    Butte, Montana

  • GSK Investigational Site

    Lincoln, Nebraska

  • GSK Investigational Site

    Las Vegas, Nevada

  • GSK Investigational Site

    Belleville, New Jersey

  • GSK Investigational Site

    Neptune City, New Jersey

  • GSK Investigational Site

    Albany, New York

  • GSK Investigational Site

    Brooklyn, New York

  • GSK Investigational Site

    Lima, Ohio

  • GSK Investigational Site

    Toledo, Ohio

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Channelview, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.